Arias GE, Otero MF, Acosta RRA

Language: Spanish
References: 9
Page: 63-66
PDF size: 124.64 Kb.

REFERENCES

1. Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus infection (RSV).

2. American Academy of Pediatrics (AAP). RSV (respiratory syncytial virus).

3. Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017; 390 (10098): 946-958.

4. World Health Organization (WHO). Respiratory syncytial virus.

5. Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020; 383 (5): 415-425.

6. Datos y estudios nacionales sobre la hospitalización y cuidado intensivo por VRS, basados en los informes y registros de la Secretaría de Salud de México y otros estudios locales disponibles en bases de datos médicas y académicas. https://www.gob.mx/salud/documentos/informes-semanales-para-la-vigilancia-epidemiologica-de-influenza-covid-19-y-otros-virus-respiratorios-2024.

7. Mankad VS, Leach A, Chang Y, Wahlby Hamrén U, Kiazand A, Kubiak RJ et al. Comprehensive summary of safety data on nirsevimab in infants and children from all pivotal randomized clinical trials. Pathogens. 2024; 13 (6): 503. doi: 10.3390/pathogens13060503.

8. Vittucci AC, Antilici L, Dotta A, Cutrera R, Villani A. Respiratory syncytial virus infection: new prevention strategies. Glob Pediatr [Internet]. 2024; 7: 100130. Available in: https://doi.org/10.1016/j.gpeds.2023.100130

9. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009; 360 (6): 588-598. doi: 10.1056/NEJMoa0804877.